The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Employers face rising GLP-1 demand. Here are tips to manage costs while maintaining care access.

Eli Lilly shares are now positive for the year, up 10% since the start of January.

A diverse range of medical specialists offer unique expertise for obesity treatment. “Endocrinologists, bariatricians, obesity specialists and psychiatrists can prescribe weight loss medication,” ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

Sen. John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Studies show that GLP-1 agonists can help patients lose 5-15% of their body weight when combined with diet and exercise.